PSNCBAM‐1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background and purpose: Rimonabant (Acomplia TM, SR141716A), a cannabinoid CB 1 receptor inverse agonist, has recently been approved for the treatment of obesity. There are, however, concerns regarding its side effect profile. Developing a CB 1 antagonist with a different pharmacological mechanism may lead to a safer alternative. To this end we have screened a proprietary small molecule library and have discovered a novel class of allosteric antagonist at CB 1 receptors. Herein, we have characterized an optimized prototypical molecule, PSNCBAM‐1, and its hypophagic effects in vivo. Experimental approach: A CB 1 yeast reporter assay was used as a primary screen. PSNCBAM‐1 was additionally characterized in [35 S]‐GTPγS, cAMP and radioligand binding assays. An acute rat feeding model was used to evaluate its effects on food intake and body weight in vivo. Key results: In CB 1 receptor yeast reporter assays, PSNCBAM‐1 blocked the effects induced by agonists such as CP55,940, WIN55212‐2, anandamide (AEA) or 2‐arachidonoyl glycerol (2‐AG). The antagonist characteristics of PSNCBAM‐1 were confirmed in [35 S]‐GTPγS binding and cAMP assays and was shown to be non‐competitive by Schild analyses. PSNCBAM‐1 did not affect CB 2 receptors. In radioligand binding assays, PSNCBAM‐1 increased the binding of [3 H]CP55,940 despite its antagonist effects. In an acute rat feeding model, PSNCBAM‐1 decreased food intake and body weight. Conclusions and implications: PSNCBAM‐1 exerted its effects through selective allosteric modulation of the CB 1 receptor. The acute effects on food intake and body weight induced in rats provide a first report of in vivo activity for an allosteric CB 1 receptor antagonist. British Journal of Pharmacology (2007) 152, 805–814; doi:10.1038/sj.bjp.0707347; published online 25 June 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 10×
“At least two cannabinoid receptor subtypes are known to exist, CB1 and CB2 (Matsuda et al., 1990; Munro et al., 1993), and there is also evidence for a CB3 receptor (Fride et al., 2003).”
BackgroundInfluentialStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 2×
“At least two cannabinoid receptor subtypes are known to exist, CB1 and CB2 (Matsuda et al., 1990; Munro et al., 1993), and there is also evidence for a CB3 receptor (Fride et al.”
BackgroundDetermination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 2×
“The expansion of research in cannabinoid pharmacology has arisen principally from the discovery that D(9)-tetrahydrocannabinol, the major active compound in herbal cannabis, exerts its effects through cannabinoid receptors in the brain (Devane et al., 1988).”
BackgroundThe endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090 · cited 1×
“British Journal of Pharmacology (2007) 152, 805–814 & 2007 Nature Publishing Group All rights reserved 0007–1188/07 $30.00 www.brjpharmacol.org obesity, nicotine and alcohol dependence, pain, multiple sclerosis, cancer, diarrhoea and cardiovascular diseases (Di Marzo et al., 2004).”
BackgroundInfluentialLocalization of cannabinoid receptor mRNA in rat brain
Matsuda, L. A., Bonner, T. I., & Lolait, S. J. (1993) · Journal of Comparative Neurology · doi:10.1002/cne.903270406 · Cited by 631 · cited 2×
“CB2 receptors are expressed primarily in immune cells, whereas CB1 receptors exist predominantly in the brain (Matsuda et al., 1993) and to a lesser extent in peripheral tissues such as testis (Gerard et al.”
Background
Cited by
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605
Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039
“ORG27569 and PSNCBAM-1 reduce the efficacy and potency of the CB1 receptor agonists WIN55,212-2 and CP55,940 to stimulate GTPγS(35), enhance Gαi/o-dependent signalling and arrestin recruitment and inhibit CB1 receptor internalization and cAMP accumulation at submicromolar concentrations (Price et al., 2005; Horswill e…”
BackgroundResultInfluentialEmerging strategies for exploiting cannabinoid receptor agonists as medicines
Pertwee, R. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00048.x · Cited by 436
“As well as orthosteric site(s), the CB1 receptor possesses one or more allosteric sites that can be targeted by ligands in a manner that enhances or inhibits the activation of this receptor by both exogenously administered and endogenously released direct agonists (Price et al., 2005; Adam et al., 2007; Horswill et al…”
BackgroundPhytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312
State-of-the-art therapy for down syndrome
Lorenzon, N., Musoles‐Lleó, J., Turrisi, F., Gomis‐González, M., De La Torre, R., & Dierssen, M. (2023) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15517 · Cited by 22
Metadata
- Authors
- Horswill, J. G., Bali, U., Shaaban, S., Keily, J. F., Jeevaratnam, P., Babbs, A. J., Reynet, C., & Wong Kai In, P.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-11
- Volume
- 152
- Issue
- 5
- Pages
- 805-814
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1880519341
- Cited by
- 175
- References
- 6
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.